D P Steensma

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Building West 10, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Mol Diagn 8:397-411; quiz 526. 2006
  2. ncbi Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:691-8. 2008
  3. ncbi New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Support Oncol 5:471-3. 2007
  4. ncbi Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:47-53. 2005
  5. ncbi Northwoods elegy
    David P Steensma
    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
    Ann Intern Med 141:573-4. 2004
  6. ncbi Reassurance
    David P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 22:3196-8. 2004
  7. ncbi Management of anemia in patients with cancer
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 6:297-304. 2004
  8. ncbi Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations
    David P Steensma
    MRC Molecula Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
    Blood 103:2019-26. 2004
  9. ncbi Investment analysts and the American Society of Hematology
    David P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 112:29-33. 2008
  10. doi The art of oncology: when the tumor is not the target. Don't mention it
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:3083-4. 2008

Detail Information

Publications79

  1. pmc JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Building West 10, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Mol Diagn 8:397-411; quiz 526. 2006
    ..I also discuss diagnostic sensitivity, performance, and other practical concerns relevant to the clinical laboratorian in addition to the potential diagnostic utility of JAK2 mutation tests...
  2. ncbi Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:691-8. 2008
    ..Within the limitations of self-reported data, these results provide a benchmark for future interventions to improve QOL in patients with MDS...
  3. ncbi New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Support Oncol 5:471-3. 2007
  4. ncbi Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:47-53. 2005
    ..In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations...
  5. ncbi Northwoods elegy
    David P Steensma
    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
    Ann Intern Med 141:573-4. 2004
  6. ncbi Reassurance
    David P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 22:3196-8. 2004
  7. ncbi Management of anemia in patients with cancer
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 6:297-304. 2004
    ....
  8. ncbi Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations
    David P Steensma
    MRC Molecula Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
    Blood 103:2019-26. 2004
    ....
  9. ncbi Investment analysts and the American Society of Hematology
    David P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 112:29-33. 2008
    ..I also propose changes in ASH policy that may help safeguard public trust as well as preserve the access of clinicians and scientists to clinically relevant data presented at the Annual Meeting...
  10. doi The art of oncology: when the tumor is not the target. Don't mention it
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:3083-4. 2008
  11. ncbi Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 139:439-42. 2007
    ..5%) patients with myeloproliferative disorders, but in none of the acute leukaemia patients or controls. We conclude that the emergence of thalassaemic clones may be relatively common in the disordered marrow milieu of MDS...
  12. ncbi Exacerbation of asthma by Florida "red tide" during an ocean sailing trip
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1128-30. 2007
    ....
  13. ncbi Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts)
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:623-8. 2007
    ....
  14. ncbi A history of the kidney in plasma cell disorders
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Contrib Nephrol 153:5-24. 2007
    ..The kidneys are commonly injured in plasma cell dyscrasias...
  15. ncbi MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 91:ECR57. 2006
    ....
  16. ncbi JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained
    D P Steensma
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Leukemia 20:971-8. 2006
    ..Janus kinase2 extrinsic regulators and other proteins in the JAK-STAT pathway should be interrogated to explain frequent STAT activation in AML...
  17. ncbi Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    David P Steensma
    Mayo Clinic and Mayo Foundation, Rochester 55905, USA
    J Clin Oncol 24:1079-89. 2006
    ..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia...
  18. ncbi Risk-based management of myelodysplastic syndrome
    David P Steensma
    Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 21:43-54; discussion 57-8, 62. 2007
    ..While many questions remain about the optimal use of newer agents, the long-standing perception of MDS as a syndrome where therapeutic nihilism is the only realistic approach is slowly beginning to change...
  19. ncbi Luis Walter Alvarez: another "Mayo-trained" Nobel Laureate
    David P Steensma
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester MN 55905, USA
    Mayo Clin Proc 81:241-4. 2006
  20. ncbi Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity
    David P Steensma
    Department of Medicine Hematology and Oncology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Res 30:1227-33. 2006
    ..Here, I discuss evidence supporting broader consideration of MDS as a form of malignant neoplasia - i.e., cancer - as well as some of the relevant practical issues...
  21. ncbi The myelodysplastic syndromes: diagnosis and treatment
    David P Steensma
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:104-30. 2006
    ....
  22. ncbi Anemia in the elderly: how should we define it, when does it matter, and what can be done?
    David P Steensma
    Division of Hematology, Mayo Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:958-66. 2007
    ..We also outline a practical initial diagnostic approach that helps determine appropriate treatment, and we weigh therapeutic options in light of new safety concerns regarding erythropoiesis-stimulating agents...
  23. ncbi The chronic myeloproliferative disorders: an historical perspective
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 2:221-30. 2003
    ..This narrative review explores some of the most noteworthy episodes in those stories, from first descriptions to current understanding...
  24. ncbi Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, West 10, 200 First Street, SW, Rochester, MN 55905, USA
    Leuk Res 27:775-82. 2003
    ....
  25. ncbi Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 118:813-6. 2002
    ..Low-dose lung radiotherapy may be a useful palliative tool for patients with MMM complicated by PH...
  26. doi The mosaic of myeloid neoplasia: implications for classification
    David P Steensma
    Mayo Clinic, Rochester, Minnesota, USA
    Leuk Lymphoma 49:1228-9. 2008
  27. doi Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial
    David P Steensma
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:3842-8. 2009
    ..This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices...
  28. ncbi Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review
    D P Steensma
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 42:1243-53. 2001
    ..For patients who develop oscillatory variation in their platelet counts associated with HU use, keeping the HU dose constant may result in damping or termination of the cycles. However, this strategy is not always successful...
  29. ncbi Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience
    D P Steensma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 42:1229-34. 2001
    ..We discuss some of the unique concerns regarding pregnant patients with MDS. As women give birth at older ages and as more young persons survive cancer, MDS and pregnancy are likely to be seen together with increasing frequency...
  30. ncbi Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 99:2252-4. 2002
    ..Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM...
  31. ncbi Why me?
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:873-5. 2002
  32. pmc Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Res 69:7518-23. 2009
    ..These data support involvement of IER3 in the pathobiology of MDS...
  33. ncbi Hereditary red blood cell disorders in middle eastern patients
    D P Steensma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:285-93. 2001
    ..Although a detailed discussion of treatment of erythrocyte disorders is beyond the scope of this article, some general management principles are described...
  34. ncbi "Congo" red: out of Africa?
    D P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Pathol Lab Med 125:250-2. 2001
    ..Congo red is the essential histologic stain for demonstrating the presence of amyloidosis in fixed tissues. To the best of my knowledge, nothing has been written about why the stain is named "Congo."..
  35. ncbi Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2156-8. 2003
    ..We conclude that the risk-benefit ratio of ATG in an unselected population of MDS patients may be unfavorable, and more work is needed to define the subset of patients who will respond to ATG before its widespread use can be recommended...
  36. ncbi Myelodysplasia paranoia: iron as the new radon
    David P Steensma
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 33:1158-63. 2009
    ....
  37. ncbi The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss
    David P Steensma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:221-2. 2003
    ....
  38. ncbi "Pawn Ball Megakaryocytes": from the marvellous medici and dear Old Saint Nick to the unsanctified marrow of myelodysplasia
    David P Steensma
    Divsion of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hematology 8:11-8. 2003
    ..The murky history of the symbol and its significance for myelodysplasia are reviewed...
  39. ncbi Submitting to autonomy
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:62s-63s. 2003
  40. ncbi Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?
    David P Steensma
    Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:235-42. 2003
    ..Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings...
  41. ncbi Why me?
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:64s-66s. 2003
  42. ncbi The myelodysplastic syndrome(s): a perspective and review highlighting current controversies
    David P Steensma
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 27:95-120. 2003
    ..In this narrative review, we highlight recent developments and controversies within the context of current knowledge about this mysterious and fascinating cluster of bone marrow failure states...
  43. ncbi The narrow path
    David P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:57s-60s; discussion 60s. 2003
  44. ncbi Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
    R A Mesa
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 20:1800-8. 2006
    ..008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis...
  45. ncbi Polycythemia vera: plethora, from prehistory to present
    David P Steensma
    Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 4:230-4. 2005
    ..This review traces some of the principal events in the history of polycythemia vera (PV) as a discrete clinical entity...
  46. ncbi Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity
    David P Steensma
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:681-98. 2005
    ....
  47. ncbi Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
    ..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
  48. ncbi Overcoming obstacles to hospice care: an ethical examination of inertia and inaction
    Christopher K Daugherty
    Department of Medicine, MacLean Center for Clinical Medical Ethics, the Cancer Research Center at the University of Chicago, and Vitas Hospice, Chicago, IL 60637 1470, USA
    J Clin Oncol 21:42s-45s. 2003
  49. ncbi A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  50. ncbi Mutations in the chromatin-associated protein ATRX
    Richard J Gibbons
    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    Hum Mutat 29:796-802. 2008
    ..Missense mutations are shown to cluster in the two main functional domains. The truncating mutations appear to be "rescued" to some degree and so it appears likely that most if not all constitutional ATRX mutations are hypomorphs...
  51. ncbi Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 32:407-11. 2008
    ..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone...
  52. ncbi C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders
    Jonathan S C Caudill
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 133:638-41. 2006
    ..All other patients were NPM1-wild type in the region analysed. In conclusion, C-terminal NPM mutations are uncommon in chronic myeloid neoplasia, but if present may represent an evolving leukaemic clone...
  53. ncbi A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome
    Maria E Nelson
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Haematologica 90:1463-70. 2005
    ..Acquired HbH has recently been associated with mutations in an X-linked gene, ATRX, previously linked to inherited ATR-X syndrome (alpha thalassemia-retardation-X linked)...
  54. doi History of multiple myeloma
    Robert A Kyle
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Recent Results Cancer Res 183:3-23. 2011
    ..The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide...
  55. ncbi Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
    Cheng E Chee
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:611-3. 2008
    ..The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome...
  56. ncbi The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group
    Tait D Shanafelt
    Department of Oncology, Mayo Clinic, Rochester, Minn, USA
    Oncology 68:23-32. 2005
    ..While much is known about oncologist distress, little is known about oncologist well-being. We set out to evaluate oncologist well-being and the personal wellness promotion strategies used by oncologists...
  57. pmc The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
    David P Steensma
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester MN 55905, USA
    Blood 106:1207-9. 2005
    ..The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders...
  58. ncbi Cytogenetic and molecular genetic aspects of essential thrombocythemia
    David P Steensma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Acta Haematol 108:55-65. 2002
    ..In the future, global analysis of gene expression patterns may help overcome diagnostic dilemmas, refine disease classification, and lead to an improved understanding of the pathogenesis of ET...
  59. ncbi Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
    ..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
  60. ncbi The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
    Ruben A Mesa
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:1199-203. 2009
    ..The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials...
  61. doi Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
    Ayalew Tefferi
    Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:265-7. 2009
    ..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value...
  62. ncbi The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:320-8. 2005
    ....
  63. ncbi Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  64. ncbi Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience
    Carrie A Thompson
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:405-7. 2006
    ..However, treatment-related morbidity was high, with frequent infectious complications...
  65. ncbi Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis
    Paul J Thurmes
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 77:57-60. 2006
    ..The purpose of this study was to use JAK2 V617F analysis to re-evaluate the validity of elevated Epo levels as a PV-exclusion criterion in patients with hepatic vein thrombosis [Budd-Chiari syndrome (BCS)]...
  66. doi Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Res 32:1927-30. 2008
    ..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology...
  67. ncbi A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death
    D P Steensma
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 97:2522-3. 2001
    ..0001). These findings suggest that a high PCLI in patients with apparently stable, plateau phase MM is an adverse parameter that may predict a short time to disease progression and death...
  68. ncbi Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome
    A Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 25:183-5. 2001
    ..None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS...
  69. ncbi Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome
    David P Steensma
    Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington Oxford OX3 9DU, United Kingdom
    Blood 103:1518-20. 2004
    ....
  70. pmc Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study
    R Savica
    Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1381-7. 2009
    ..Thus, we investigated the association of anemia with the subsequent risk of PD using a case-control study design...
  71. ncbi MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    Animesh D Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 108:3472-6. 2006
    ..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease...
  72. ncbi Overcoming obstacles to hospice care: an ethical examination of inertia and inaction
    Christopher K Daugherty
    Department of Medicine, MacLean Center for Clinical Medical Ethics, the Cancer Research Center at the University of Chicago, IL, USA
    J Clin Oncol 20:2752-5. 2002
  73. ncbi On the TRAIL of a new therapy for leukemia
    S H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 19:2195-202. 2005
    ..Collectively, the reviewed studies not only illustrate the potential therapeutic usefulness of TRAIL and the agonistic antibodies, but also highlight the need for additional preclinical evaluation of these agents...
  74. ncbi Epoetin alfa and darbepoetin alfa go head to head
    David P Steensma
    J Clin Oncol 24:2233-6. 2006
  75. ncbi A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur J Haematol 76:432-5, 453. 2006
    ..R2407X). This case provides further evidence for a link between ATRX mutations and ATMDS, and suggests a possible role for the conserved Q-box element in ATRX function...
  76. ncbi Sir Charles Sherrington--"The William Harvey of the nervous system"
    Marc A Shampo
    Mayo Clin Proc 80:1266. 2005
  77. ncbi Is anemia of cancer different from chemotherapy-induced anemia?
    David P Steensma
    J Clin Oncol 26:1022-4. 2008
  78. doi Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents
    David P Steensma
    Am J Hematol 83:693-4. 2008
  79. ncbi Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate
    Ruben A Mesa
    Br J Haematol 123:366-7. 2003